Address concerns or make changes to your treatment plan at any stage of your journey with Klinic in New York
Expecting hunger cues to stay muted indefinitely
Ma B, Wang X, Ren H, Li Y, Zhang H, Yang M, et al
24.2% average weight loss over 48 weeks
Recommendations- To take advantage of the opportunities, The Business Research Company recommends the GLP-1 receptor agonist companies to focus on expanding oral and patient-centric GLP-1 therapies, focus on advancing dual GLP-1/GIP therapies for superior obesity outcomes, focus on developing dual GLP-1/glucagon agonists for metabolic liver disease, focus on expanding semaglutide and tirzepatide offerings to capture high-growth segments, focus on expanding oral glp-1 therapies to capture rapidly growing market demand, focus on wind power systems as the fastest-growing segment, focus on variable speed drives to capture high-growth opportunities, focus on expanding distribution channels across non-traditional care settings, focus on strategic pricing to enhance market access and competitiveness, focus on educating healthcare providers to drive adoption, focus on patient-centric awareness campaigns to expand engagement, focus on expanding GLP-1 access through other users channels.
